News

Lancet accuses AstraZeneca of sponsoring biased research

BMJ 2003; 327 doi: https://doi.org/10.1136/bmj.327.7422.1005-a (Published 30 October 2003) Cite this as: BMJ 2003;327:1005
  1. Owen Dyer
  1. London

    The Lancet last week took the unprecedented step of accusing Europe's second biggest drug company, AstraZeneca, of sponsoring biased research into its new anticholesterol drug rosuvastatin (Crestor).


    Embedded Image

    Dr Richard Horton: doctors “must tell their patients the truth about rosuvastatin”

    In an editorial, the journal's editor, Richard Horton, said the company's tactics “raise disturbing questions about how drugs enter clinical practice and what measures exist to protect patients from inadequately investigated medicines”(Lancet 2003;362: 1341).

    The Galaxy series …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe